Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 21, 2013; 19(43): 7680-7695
Published online Nov 21, 2013. doi: 10.3748/wjg.v19.i43.7680
Published online Nov 21, 2013. doi: 10.3748/wjg.v19.i43.7680
Figure 6 Wnt3a treatment antagonized the inhibitory effects of 8-bromo-7-methoxychrysin.
Wnt3a treatment resulted in an increase in the expression of β-catenin in both liver cancer stem cells (LCSCs) and parental MHCC97 cells (A) and attenuated the effects of 8-bromo-7-methoxychrysin (BrMC) on the expression of β-catenin (B) and stem cell markers (C), and self-renewal capacity (D) of LCSCs derived from the MHCC97 cell line. aP < 0.05 vs CD133+ SFCs, cP < 0.05 vs 0.1 μmol/L BrMC or Wnt 3a alone treated group.
-
Citation: Quan MF, Xiao LH, Liu ZH, Guo H, Ren KQ, Liu F, Cao JG, Deng XY. 8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells
via downregulation of β-catenin. World J Gastroenterol 2013; 19(43): 7680-7695 - URL: https://www.wjgnet.com/1007-9327/full/v19/i43/7680.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i43.7680